TBio-6517

AXP000104.1 · Oncolytic virus

Platform
vaccinia virus (Copenhagen, TK-)
Originator
Turnstone Biologics
Sponsor
Turnstone Biologics

Names

NameTypeSource
TBio-6517preferred name, codecurator, ctgov
RIVAL-01codencit

Virus

Role
Oncolytic
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
Copenhagen
Replication
conditionally replicating
Modifications
thymidine kinase deleted
Transgenes
FLT3LG, anti-CTLA-4 antibody, IL12A, IL12B
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C174049

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04301011Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid TumorsTerminatedPhase 12020-06-022023-01-2327Cervical Cancer; Cutaneous Squamous Cell Carcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma; Melanoma (Skin); Mesothelioma; Microsatellite Stable Colorectal Cancer; Oropharynx Cancer; Renal Cell Carcinoma; Solid Tumor

Recent changes

No changes recorded in its trials yet.

Notes

Also called RIVAL-01. Expresses Flt3 ligand, an anti-CTLA-4 antibody and IL-12; phase 1/2a with pembrolizumab (NCT04301011) terminated January 2023 and the programme dropped.

How to cite

TBio-6517 (AXP000104.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000104.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.